

Overview of CML related sessions at 25th EHA Annual Congress (Virtual Meeting)

Time slots	Sessions
Live Sessions	
Thu, 11 June 10.15 – 11.45	<p>Satellite Symposium: Expert insights into CML and classical MPNs treatment intervention: The ‘when’ and the ‘how’ (Supported by Novartis)</p> <p>Chair: F Heidel (Jena, Germany)</p> <p>Program:</p> <ul style="list-style-type: none"> • Opening and introduction (F Heidel) • Treating earlier in myelofibrosis (S Verstovsek) • Monitoring to achieve treatment goals in CML (H Erba) • Unmet needs in CML with focus on the 3L+ (T Hughes) • Novel approaches to predicting responses in polycythemia (F Heidel) • Concluding remarks (F Heidel)
Sun, 14 June 17.30 – 18.30	<p>COVID-19 and Hematology Session: Part 1: Basis pathobiology Chair: D Wolf (Austria)</p>
Sun, 14 June 18.45 – 19.45	<p>COVID-19 and Hematology Session: Part 2: Clinical management Chair: K Döhner (Ulm, Germany)</p>
Sun, 14 June 20.00 – 21.00	<p>COVID-19 and Hematology Session: Part 3: Treatment – current and future Chair: R Lassila (Helsinki, Finland)</p>

Time slots	Sessions
Fri, 19 June 18.00 – 18.45	<p>Live Q&A Panel Discussion: CML Clinical Oral Session</p> <p>Chairs:</p> <ul style="list-style-type: none"> • H Hjort-Hansen (Trondheim, Norway) • S Saussele (Mannheim, Germany) <p>Speakers:</p> <ul style="list-style-type: none"> • Timothy Hughes (Adelaide, Australia) • Katerina Machova Polakova (Prague, Czech Republic) • Jorge Cortes (Augusta, USA) • Lydia Roy (Cretail, France) • Hjalmar Flygt (Uppsala, Sweden)
Fri, 19 June 19.00 – 19.45	<p>Live Q&A Panel Discussion: Mechanisms and strategies to address TKI resistance and stem cell persistence in CML Oral Session</p> <p>Chair: TBA</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Jake Ritchie (Glasgow, UK) • Ingmar Glauche (Dresden, Germany) • Rebecca Mitchell (Glasgow, UK) • Patrick Harrington (London, UK) • Anna Sicuranza (Siena, Italy)
Fri, 19 June 20.00 – 20.45	<p>Live Q&A Panel Discussion: Current challenges in chronic myeloid leukemia (CML) treatment</p> <p>Chair: A Almeida (Lisbon, Portugal)</p>

Time slots	Sessions
Fri, 19 June 20.00 – 20.45	<p>Education Session</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Ravi Bhatia (Birmingham, USA) • Simona Soverini (Bologna, Italy) • Jane Apperley (London, UK)
Fri, 19 June 21:00 – 21.45	<p>Live Q&A Panel Discussion: Treating resistance in chronic myeloid leukemia (CML)</p> <p>Chair: O Hantschel (Marburg, Germany)</p> <p>Hematology-in-focus</p> <p>Speakers:</p> <ul style="list-style-type: none"> • A Hochhaus (Jena, Germany) • D Ross (Adelaide, Australia)
On-demand sessions	
	<p>Oral Session: CML Clinical</p> <p>Chairs:</p> <ul style="list-style-type: none"> • H Hjorth-Hansen (Trondheim, Norway) • S Saussele (Mannheim, Germany) <p>Program:</p> <ul style="list-style-type: none"> • (S170): Asciminib in heavily pre-treated patients (T Hughes) • (S171): Major molecular response in the threshold for NGS analysis and resistant BCR-ABL1 mutation detection in CML (K Machova-Polakova) • (S172): Interim analysis from the OPTIC trial (3 starting doses for ponatinib) (J Cortes) • (S173): Dasatinib plus peg-interferon alpha 2b combination in newly diagnosed CML (L Roy)

Time slots	Sessions
	<ul style="list-style-type: none"> (S174): High-level of successful TKI discontinuation outside clinical trials – A population based study from the Swedish CML registry (H Flygt)
	<p>Education Session: Current challenges in CML treatment Chair: A Almeida (Lisbon, Portugal) Program:</p> <ul style="list-style-type: none"> Biology and targeting of CML cells (R Bhatia) Resistance to TKIs and new treatment targets (S Soverini) Which TKI and when? (J Apperley)
	<p>Science-in-focus: Epigenetic targeting in myeloid malignancies Chair: F Damm (Berlin, Germany) Program:</p> <ul style="list-style-type: none"> Targeted inhibition of epigenetic modifiers in leukemia (J Grembecka) Epigenetic profiling and therapies in MDS/AML (K Grønbaek)
	<p>Science-in-focus: Functional genomics in myeloid disease Chair: R Padua (Paris, France) Program:</p> <ul style="list-style-type: none"> Single cell genomics in MPN (A Mead) RNA based methods to explore novel leukemia treatment targets (J Zuber)
	<p>Oral Session: Mechanisms and strategies to address TKI resistance and stem cell persistence in CML Chair: TBA Program:</p> <ul style="list-style-type: none"> (S165): Identification of a drug-able dopamine receptor mediated pathway that is critical for CML stem

Time slots	Sessions
	<p>cell survival (J Ritchie)</p> <ul style="list-style-type: none"> (S166): Model-based inference and classification of immunological control mechanisms from TKI cessation and dose reduction in CML patients (I Glauche) (S167): Mechanistic and therapeutic insights into PCR2 reprogramming in blast phase CML (R Mitchell) (S168): Mechanistic insights into the inhibition of T regulatory cells by dasatinib in CML patients with clonal lymphocytosis (P Harrington) (S169): Peripheral blood CD 26+ leukemia stem cells and TKI discontinuation in CML patients: Interim analysis of prospective FLOWER-TFR study (A Sicuranza)
	<p>Hematology-in-focus: Treating resistance in chronic myeloid leukemia (CML)</p> <p>Chair: O Hantschel (Marburg, Germany)</p> <p>Program:</p> <ul style="list-style-type: none"> Clinical management beyond second line (A Hochhaus) Novel drugs and targets (D Ross)
Abstracts	
	<p>e-Poster Presentations: Chronic myeloid leukemia – Biology & translational research</p> <ul style="list-style-type: none"> (EP727): Investigating the immunological interactions after TKI therapy cessation in CML patients: Predictions and risk management using mathematical models (E Karg) (EP728): Characterization of phenotypic and genotypic markers as predictors of relapse during treatment-free remission in patients with chronic myeloid leukemia (A Luna) (EP729): SETD2/KDM4A-mediated H3K36ME3 loss in chronic myeloid leukemia patients in blast crisis can be therapeutically targeted (M Mancini) (EP730): Dasatinib induces endothelial to mesenchymal transition in human vascular endothelial cells (L Alkebsi) (EP731): The CRISP/CAS9 system efficiently reverts the tumorigenic ability of BCR/ABL and restoring

The International CML Foundation is registered as charity no. 1132984 in England and Wales

Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK

Board of Directors: T Hughes (Chair) – J Apperley - M Baccarani - J Cortes - B Druker - A Hochhaus – M Mauro - J Radich – G Saglio - C Schiffer

E-Mail: info@cml-foundation.org, Web: www.cml-foundation.org

Time slots	Sessions
	<p>the normal haematopoiesis in a mouse model of chronic myelogenous leukaemia (E Vuelta)</p> <ul style="list-style-type: none"> • (EP732): SNPS in ADC genes correlates with molecular response in CML patients treated with nilotinib (F Loscocco) • (EP733): Digital PCR for the measurement of BCR-ABL1 in CML: A new down (S Scott) • (EP735): Digital droplet PCR is a fast and effective tool for detecting T315I mutation in chronic myeloid leukemia (S Galimberti) • (EP736): Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcript (J Petiti) • (EP737): XPERT &#174; BCR-ABL Ultra: A method of monitoring conversion stability in diagnostic laboratories (K Dominy) • (EP738): Imatinib is able to interfere with immune response and inflammation in chronic myeloid leukemia patients: Results from the nanospring application (S Galimberti) • (EP739): Do not waste the data: A pipeline for evaluation of BCR-ABL1 kinase domain mutation using individual thresholds (A Benesova)
	<p>e-Posters presentations: Chronic myeloid leukemia – Clinical</p> <ul style="list-style-type: none"> • (EP740): Dose optimization of second-line bosutinib in elderly CML patients: Final results of the BEST study (F Castagnetti) • (EP741): The rate of initial BCR-ABL1 decline after commencing tyrosine kinase inhibitor therapy is predictive of both treatment-free remission eligibility and subsequent sustained treatment-free remission (N Shanmuganathan) • (EP742): Individual molecular response evaluation on both DNA and MRNA BCR-ABL1 level diminished differences in time to molecular response achievement between CML patients with E13A2 vs. E14A2 transcript type (K Machova Polakova) • (EP743): Molecular response by 24 months of nilotinib 300 mg BID treatment in patients with chronic

Time slots	Sessions
	<p>myeloid leukemia (CML) who failed to achieve DMR with imatinib: Results from the ENESTPath study (D Rea)</p> <ul style="list-style-type: none"> • (EP744): Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: A population-based study in The Netherlands 2001 – 2017 (G Ector) • (EP745): Interim report on molecular response and QoL in patients older than 60 years with Ph+ CML in MR3.0/MR4.0 stable molecular response intermittently treated with tyrosine kinase inhibitors (Italian phase III OPTKIMA study) (M Malagola) • (EP746): HLA polymorphisms predict treatment-free remission following TKI discontinuation in patients with chronic myeloid leukemia (H Ureshino) • (EP747): Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission (P Rousselot) • (EP748): Identification of genomic variants associated with long-term molecular response to tyrosine kinase inhibitors in CML (Z Iqbal) • (EP749): A phase 2 study of nilotinib in pediatric patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia (CML): Analysis of growth after ≥ 48 treatment cycles (N Hijiya) • (EP750): Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors: Analysis from the BEYOND study (V Garcia Gutierrez) • (EP751): Efficacy and safety of nilotinib in chronic myeloid leukemia patients who relapsed after discontinuation of imatinib in treatment-free remission: Results of the French NILO post-STIM study (S Duluq) • (EP752): Ponatinib at a lower dose is a good option in chronic myeloid leukemia (CML) patients intolerant to previous TKIs (A Iurlo) • (EP753): Long-term follow-up of chronic myelogenous leukemia patients with clonal chromosomal aberrations in Philadelphia-negative cells treated with tyrosine kinase inhibitors (C Varelas) • (EP754): Favourable outcome in patients with chronic myeloid leukemia co-expressing E13A2 and E14A2 transcript treated frontline with nilotinib (MP Simula) • (EP755): Is BCR-ABL1 transcript a reliable marker after allogeneic stem cell transplantation (Allo-

Time slots	Sessions
	<p>SCT): Long-term follow-up of allografted patients with BCR-ABL1 fluctuation (A Bruzzese)</p> <ul style="list-style-type: none"> • (EP756): Dasatinib in patients (pts) with chronic myeloid leukemia in chronic-phase (CML-CP) and suboptimal responses to 3 months of imatinib therapy: 3-year extended follow-up from DASCERN (J Cortes) • (EP757): Second generation TKIs in the first line can reduce time to treatment-free remission in patients with CML (O Shukhov) • (EP758): Targeting dipeptidylpeptidase IV (CD26) for a second TKI discontinuation attempt in patients with CML: Design and phase 1 results of the DOLPHIN-STAR study (C Kockerols) • (EP759): Retrospective independent review of arterial occlusive events (AOES) in the phase PACE trial of ponatinib in Philadelphia chromosome positive (Ph+) leukemia (J Januzzi) • (EP760): Imatinib corrects immune exhaustion of cytotoxic T-lymphocytes in patients with CML (F Saj) • (EP761): Determinants of first line therapy choice in chronic-phase chronic myeloid leukemia: A real-life survey in Italy (M Tiribelli) • (EP762): Next generation sequencing identifies common mutational signatures in novel genes representing different biological pathways associated with acute transformation in CML (Z Iqbal) • (EP763): Induction and maintenance for chronic myeloid leukemia chronic-phase: A novel pathway strategy (A Jain) • (EP764): A cross talk between treatment-free remission and CML population aging (M Delord) • (EP765): The real-life study evaluating the efficacy and safety of ponatinib “topase” reveals induction of deep molecular responses in a cohort of 75 TKI-resistant or intolerant patients with CML (A Turkan) • (EP766): Bosutinib in chronic-phase chronic myeloid leukemia after imatinib failure: ≥ 8 year update of a phase 1/2 study (J Cortes) • (EP767): Long-term outcomes of tyrosine kinase inhibitor in third-line therapy of chronic-phase chronic myeloid leukemia patients (T Chitanava)

Time slots	Sessions
	<p>Abstracts – publication only: Chronic myeloid leukemia – Biology & translational research</p> <ul style="list-style-type: none"> • (PB1933): Decision to stop tyrosine kinase inhibitors (TKIs) with bone marrow leukemic stem cell level: Detection of BCR-ABL in peripheral blood may not be enough (ZN Ozdemir) • (PM1934): Global gene expression and specific MRNA-MIRNA interactions in patients with CML prior to and 3, 6, and 12-months after introduction of TKI therapy (Z Ulanczyk) • (PB1935): Modelling chronic myeloid leukemia in zebrafish (S Bernardi) • (PB1936): Clinical significance of large E3 ubiquitin ligase HERC1 in chronic myelogenous leukemia (M Shahzad Ali) • (PB1937) Novel BCR-ABL1 kinase domain mutations in Russian patients resistant to all generations of TKIs (A Abdullaer) • (PB1938): Expression of level Mir-17-92 genes in patients with chronic myeloid leukemia in different phases of disease (A Lyamkina) • (PB1939): Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients: A Tunisian experience (R Frikha) • (PB1940): Targeting autophagy overcomes imatinib resistance through the inhibition of histone deacetylases in chronic myeloid leukemia cells (ES Yoo) • (PB1941): Impact of the major BCR-ABL1 transcript type on clinical and biological parameters in Western Algerian patients with chronic myeloid leukemia (M Nachi) • (PB1942): In vitro investigation of the impact of BCR-ABL tyrosine kinase inhibitors on endothelial cells (H Haguet)
	<p>Abstracts – publication only: Chronic myeloid leukemia – Clinical</p> <ul style="list-style-type: none"> • (PD1943): Molecular response rate and safety in chronic phase chronic myeloid leukemia patients who switched to generic imatinib: Long-term analysis (E Scalzulli) • (PD1944): Health-related quality of life in patients with chronic myeloid leukemia who discontinued treatment (A Shacham Abdulafia)

Time slots	Sessions
	<ul style="list-style-type: none"> • (PD1945): Discontinuation of tyrosine kinase inhibitor (TKI) therapy in CML in chronic phase (CML-CP) in US clinical practice after guideline updates (X Cao) • (PD1946): The prevalence of secondary malignancies among 234 patients with CML treated with tyrosine kinase inhibitor – single centre report (E Szczepanek) • (PD1947): Chronic myeloid leukemia in adolescents and young adults: Differences with other age groups in a multicentric cohort from Argentina (M Pagani) • (PD1948): Five years of experience of BCR-ABL testing in the evaluation of non-lymphocytic leucocytosis (C Smith) • (PD1949): Evaluation of laboratory and instrumental indicators of heart failure in patients with CML undergoing treatment with tyrosine kinase inhibitors (N Shnalieva) • (PD1950): Analysis of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients as part of daily clinical practice in hospitals of the Canary Islands, Spain (A Segura Díaz) • (PD1951): Dose reduction of second generation tyrosine kinase inhibitor in chronic myeloid leukemia patients with major deep molecular remission (M Gurianova) • (PD1952): Endocrine effects induced by tyrosine kinase inhibitors during the treatment of chronic myeloid leukemia (S Bougherira) • (PD1953): Characteristics of chronic myeloid leukemia patients with primary and secondary failure to standard dose of imatinib in first line and their response to second TPEAT &#1052; EHT line (D Lekovic) • (PD1954): Generic imatinib treatment in CML. Algerian study over 12 years (2007-2018): About 881 cases, GAT-LMC (D Laklan Khadidja) • (PD1955): The evolution of the treatment of chronic myeloid leukemia: A nationwide population-based study in Taiwan (C-J Liu) • (PD1956): Preliminary results of the first tyrosine kinase inhibitor discontinuation study in patients with chronic myeloid leukemia who achieved deep and sustained molecular remission in Argentina (Argentina STOP trial – AST) (A Varela) • (PD1957): Secondary malignancies in chronic myeloid leukemia: A single centre experience

Time slots	Sessions
	<p>(M Pina Simula)</p> <ul style="list-style-type: none"> • (PD1958): Impact to inequities in access in the response to tyrosine kinase inhibitors in Colombian patients with chronic myeloid leukemia: First renehoc report on CML (V Abello) • (PD1959): Long-term outcomes of tyrosine kinase treatment for chronic myeloid leukemia: A real world data from Malaysia (A Zahiyy Mohamed) • (PD1960): The importance of molecular monitoring chronic myeloid leukemia (CML) patients on month 3 and 12 in low income countries like Albaina (A Cili) • (PD1961): Demographic/clinical factors and treatment outcomes of chronic phase chronic myeloid leukemia patients in Turkey: Real-world data (G Saydam) • (PD1962): An investigational survey in Central China: Tyrosine kinase inhibitor de-escalation treatment in chronic myeloid leukemia patients (W Li) • (PD1963): BCR-ABL1 transcript E13A2 and E14A2 in relation to survival and molecular responses in chronic myeloid leukemia patients in Bosnia (A Kurtovic-Kozaric) • (PD1964): Chronic myeloid leukemia: 114 cases (H Khibri) • (PD1965): Rare BCR-ABL transcripts in chronic myeloid leukemia: E6A2 with extramedullary lesions and unusual E2A2 with partial deletion and simultaneous insertion (Case reports) (A Misyurin) • (PD1966): Evaluation of the selectivity of BCR-ABL tyrosine kinase inhibitors (TKIs): A systematic review (H Haguet) • (PD1967): Real world data of treatment-free remission in patients with chronic myeloid leukemia (CML) treated in tertiary care oncology centre from India (L Kashyap) • (PD1968): A case of preleukemic chronic myeloid leukemia following chemotherapy and autologous transplantation for T-lymphoblastic lymphoma (H Choi) • (PD1969): #10 year challenge CML: Single centre real-life experience on CML management. Outcomes of evolving treatment strategies (G Binotto) • (PD1970): Therapeutic results of 2nd generation tyrosine kinase inhibitors in the treatment of CML (O

Time slots	Sessions
	<p>Kassar)</p> <ul style="list-style-type: none"> • (PD1971): PONS – A phase 2 study with ponatinib as a 2nd generation therapy for patients with CML in chronic-phase who are resistant or intolerant to prior 1st line tyrosine kinase inhibitors (P Le Coutre) • (PD1972): Prevalence of imatinib in chronic myeloid leukemia (CML): Experience from a tertiary care centre in Eastern India (D Bhattacharyya)